Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc

被引：0
|
作者：
机构：
来源：
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN) | 2019年 / 1021卷
关键词：
CELL LUNG-CANCER; OPEN-LABEL PHASE-3; ADVANCED MELANOMA; COST-EFFECTIVENESS; PEMBROLIZUMAB; NIVOLUMAB; CHEMOTHERAPY; IPILIMUMAB; DOCETAXEL; MULTICENTER;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：314 / 331
页数：18
相关论文
共 50 条
  • [21] Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
    Thuru, Xavier
    Magnez, Romain
    El-Bouazzati, Hassiba
    Vergoten, Gerard
    Quesnel, Bruno
    Bailly, Christian
    CANCERS, 2022, 14 (14)
  • [22] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing
    Chen, Yun
    Li, Xiaojuan
    Long, Shunqin
    Shi, Yao
    Yu, Yaya
    Wu, Wanyin
    Han, Ling
    Wang, Sumei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [24] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Yang, Tianrui
    Kong, Ziren
    Ma, Wenbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
  • [25] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [26] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [27] Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
    Naidoo, Jarushka
    Schindler, Katja
    Querfeld, Christiane
    Busam, Klaus
    Cunningham, Jane
    Page, David B.
    Postow, Michael A.
    Weinstein, Alyona
    Lucas, Anna Skripnik
    Ciccolini, Kathryn T.
    Quigley, Elizabeth A.
    Lesokhin, Alexander M.
    Paik, Paul K.
    Chaft, Jamie E.
    Segal, Neil H.
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Wolchok, Jedd D.
    Lacouture, Mario E.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (05) : 383 - 389
  • [28] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [29] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
12345